MedAvail Holdings, Inc.

NasdaqCM:MDVL Lagerbericht

Marktkapitalisierung: US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MedAvail Holdings Management

Management Kriterienprüfungen 1/4

MedAvail Holdings CEO ist Mark Doerr , ernannt in Jan 2022, hat eine Amtszeit von 2.08 Jahren. Die jährliche Gesamtvergütung beträgt $2.52M , bestehend aus 16.8% Gehalt und 83.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.23% der Aktien des Unternehmens, im Wert von $6.79K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 2.7 Jahre.

Wichtige Informationen

Mark Doerr

Geschäftsführender

US$2.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts16.80%
Amtszeit als Geschäftsführer2.1yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.7yrs

Jüngste Management Updates

Recent updates

Analyseartikel • Aug 17

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

MedAvail Holdings, Inc. ( NASDAQ:MDVL ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Aug 02

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail is a prescription drug-dispensing kiosks startup whose revenues are growing by over 100% year-on-year at the moment. However, the gross margin is barely positive and the operating loss expanded to $12.8 million in Q1 2022. Cash used in operational activities rose to $13.3 million in Q1 2022 and I think that the company will need another capital increase around the end of the year. However, short selling seems dangerous at the moment as the short borrow fee rate is almost 80%. Introduction I like writing about under covered stocks on SA, and today I'm taking a look at MedAvail Holdings (MDVL). It's a company focused on pharmacy automation kiosks and the growth of its business looks compelling. However, the operating expenses are high and the company is set to run low on cash again soon. I think that another stock dilution seems inevitable in the near future. Overall, I don't think that the business is worth much in its current state and I'm bearish. Let's review. Overview of the business and financials MedAvail is a pharmacy technology and services company whose main product is a MedCenter. This is a pharmacist controlled, customer-interactive, prescription dispensing system that looks somewhat like an ATM on the outside. MedAvail It's an interesting concept but there are several competitors with a similar business, including Omnicell (NASDAQ: OMCL) Dispension Industries, Pharmaself24. What MedAvail is offering doesn't seem to be unique. The company also operates full-service retail pharmacies under the SpotRx brand that use its automated pharmacy technology. MedAvail has bet on a hub and spoke model and it currently has operations in the states of Arizona, California, Michigan, and Florida. It plans to set foot in Texas and Illinois in the near future. MedAvail has partnered with several large brands, including IMA Medical Group, CareMore Health, Cigna (NYSE: CI), and Cano Health. MedAvail The dispensing units usually ramp up to $1 million in annual revenues by their second year. As of December 2021, MedAvail had a total of 13 dispensing units that were operating for over 18 months, and it plans to set up about 25-30 dispensing units in 2022. For the graphs below, note that net cumulative deployments exclude decommissioned clinics, pilot and demo sites. MedAvail MedAvail In Q1 2022, retail pharmacy and hardware revenues increased by 126.3% year-on-year thanks to a $5.4 million increase from volume growth in prescription revenue at existing sites as well as new sites in Florida and Michigan. Unfortunately, there don't appear to be significant economies of scale as the total cost of products sold and services soared by 132.3% to $8.61 million. In addition, operating expenses rose by 33.1% which led to a widening of the operating loss of MedAvail to $12.8 million in Q1 2022. MedAvail Looking at the future, the targeted milestones listed in MedAvail's latest corporate presentation include increasing the network of dispensing MedCenters to more than 100 in existing markets. I don't think this should be hard to achieve considering there were already 88 dispensing units in operation as of March 2022, up from 68 units in December 2021. The company also aims to reduce its quarterly cash burn by 20% by improving its gross margin and achieving greater hub pharmacy utilization. It also highlighted a procurement strategy for sourcing pharmaceuticals at optimal cost to drive utilization and the appropriate mix of medications. However, I don't see a path to profitability anytime soon considering the gross margin hasn't seen much improvement over the past few quarters and that the operating loss has increased by over 37% in just a year. In my view, this is a major issue as it has led to an increase of net cash used in operating activities to $13.3 million in Q1 2022, compared to $9.8 million a year earlier. As a result, MedAvail closed March with cash and cash equivalents of only $5.27 million. The company then raised $40 million through the issuance of 37.6 million shares at $1.0625 apiece in April 2022. Yet, I think that another large private placement is likely to take place around the end of 2022 due to the increase of cash used in operating activities. I think that more stock dilution seems inevitable at the moment. Turning our attention to the balance sheet, we can see that MedAvail has an asset-light business model and cash, receivables, and inventories accounted for almost half of the $27.7 million in total assets at the end of Q1 2022. I find it concerning that the accumulated deficit has surpassed $200 million. MedAvail Overall, I expect MedAvail to continue growing its revenues at a rapid pace and I think the annual run rate could surpass $50 million by the end of 2022. However, the gross margin is barely positive and when you add operating expenses, the picture isn't pretty. And with net cash used in operations growing rapidly, I think that another large capital increase is likely in a few months. I'm bearish but I don't think that this is a good time to be short selling MedAvail. According to data from Fintel, there are 250,000 shares available for borrowing as of the time of writing but the short borrow fee rate is 79.39%. And if you want to rely on put options instead, the lowest available strike price at the moment is $2.50.
Analyseartikel • Aug 17

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

The latest analyst coverage could presage a bad day for MedAvail Holdings, Inc ( NASDAQ:MDVL ), with the analysts...
Analyseartikel • May 24

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

Does the May share price for MedAvail Holdings, Inc ( NASDAQ:MDVL ) reflect what it's really worth? Today, we will...
Analyseartikel • Feb 20

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

In this article we are going to estimate the intrinsic value of MedAvail Holdings, Inc ( NASDAQ:MDVL ) by taking the...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mark Doerr im Vergleich zu den Einnahmen von MedAvail Holdings verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$55m

Dec 31 2022US$3mUS$424k

-US$48m

Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD2.52M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD642.98K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Mark mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Mark Doerr (53 yo)

2.1yrs
Amtszeit
US$2,524,419
Vergütung

Mr. Mark Doerr, RPh serves as Chief Executive Officer, President and Director at MedAvail Holdings, Inc since January 10, 2022. He serves as the Chief Executive Officer of eRx Network, LLC since March 28,...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Ramona Seabaugh
CFO, Treasurer & Secretary2.4yrsUS$537.22k0.076%
$ 2.2k
Emilia Keric
Senior VP & General Counselless than a yearkeine Datenkeine Daten
Joan O'Rourke
President of SpotRx2.8yrskeine Datenkeine Daten
Brian Schlerf
Corporate Controller3.1yrskeine Datenkeine Daten
2.4yrs
Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: MDVLDas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Mark Doerr
CEO, President & Director2.1yrsUS$2.52m0.23%
$ 6.8k
Robert Faulkner
Chairman of the Board3.3yrskeine Daten0.12%
$ 3.6k
Laurie McGraw
Independent Director2.1yrsUS$217.96k0%
$ 0
Michael Kramer
Independent Director3.3yrsUS$187.00k0%
$ 0
Glen Stettin
Independent Director3.3yrsUS$170.00k0%
$ 0
Paul Johnson
Independent Director2.1yrsUS$224.96k0%
$ 0
2.7yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter

Erfahrener Vorstand: MDVLDie Vorstandsmitglieder gelten nicht als erfahren ( 2.7 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/02/03 16:47
Aktienkurs zum Tagesende2024/02/02 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

MedAvail Holdings, Inc. wird von 2 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Brooks O'NeilLake Street Capital Markets, LLC
Charles RhyeeTD Cowen